LY-339434
LY-339434 is a chemical compound that has been studied for its potential pharmacological effects. It is primarily known as a selective antagonist of the 5-HT2A receptor, a subtype of the serotonin receptor. This compound has been of interest in the field of neuropsychopharmacology due to its potential implications in the treatment of various psychiatric disorders.
Chemical Structure and Properties[edit]
LY-339434 is a synthetic compound with a complex chemical structure. It belongs to the class of phenylpiperazine derivatives, which are known for their activity on serotonin receptors. The molecular formula of LY-339434 is C20H25N3O2, and it has a molecular weight of approximately 339.44 g/mol.
Pharmacology[edit]
LY-339434 acts as a selective antagonist at the 5-HT2A receptor, which is one of the several subtypes of serotonin receptors found in the central nervous system. The 5-HT2A receptor is implicated in various neurological and psychiatric processes, including mood regulation, perception, and cognition.
Mechanism of Action[edit]
As an antagonist, LY-339434 binds to the 5-HT2A receptor and inhibits the action of serotonin (5-HT) at this site. This blockade can modulate the downstream signaling pathways that are typically activated by serotonin, potentially leading to alterations in mood, perception, and other cognitive functions.
Potential Therapeutic Applications[edit]
Research into LY-339434 has suggested potential applications in the treatment of disorders such as schizophrenia, depression, and anxiety disorders. By modulating the activity of the 5-HT2A receptor, LY-339434 may help alleviate symptoms associated with these conditions.
Research and Development[edit]
The development of LY-339434 has primarily been in the preclinical stage, with studies focusing on its pharmacokinetics, pharmacodynamics, and safety profile. Animal studies have been conducted to assess its efficacy and potential side effects.
Safety and Side Effects[edit]
As with many investigational drugs, the safety profile of LY-339434 is still under investigation. Common side effects observed in preclinical studies include alterations in behavior and physiological responses, which are typical of compounds affecting the central nervous system.
Also see[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
